Clinical trials: Acute Migraine
Migraine
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.
- Trial name
- NCT06848075
- Testing
- Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg
- Where
- 66 sites in United States
- Volunteers
- 431 people
- Sponsor
- TriGemX Bio, Inc.
Acute Migraine
Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
This trial is to determine whether BHV3000 (rimegepant) 75mg is safe and effictive as a treatment for acute migraine in Chinese and Korean patients
- Trial name
- NCT04574362
- Testing
- Rimegepant
- Where
- 90 sites in China, South Korea
- Volunteers
- 1,648 people
- Sponsor
- Pfizer
Migraine, With or Without Aura
Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults
The purpose of this study is to evaluate the long-term safety of BR005-036C tablets in the acute treatment of migraines
- Trial name
- NCT07835152
- Testing
- BR005-036C
- Where
- 81 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Brise Pharmaceuticals Co., Ltd.
Migraine Headache
A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack
Intraject is a needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan to be used by patients to treat acute migraine treatment.
- Trial name
- NCT00530517
- Testing
- Intraject Sumatriptan
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Zogenix, Inc.
Migraine Headache
MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)
A study to compare rizatriptan (MK0462) 5 mg by mouth (p.o.) and sumatriptan 50 mg p.o. for the acute treatment of a migraine attack.
- Trial name
- NCT00897104
- Testing
- rizatriptan benzoate (MK0462), Comparator: sumatriptan
- Volunteers
- 933 people
- Sponsor
- Organon and Co
Migraine Disorders
A Study of Lasmiditan in Participants With Migraine
The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it during an acute migraine attack and also during the time between acute migraine attacks.
- Trial name
- NCT03247790
- Testing
- Lasmiditan
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine
Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds
Study Objectives: 1. The primary objective is to characterize the pharmacokinetics of a single oral administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis of episodic migraine with or without…
- Trial name
- NCT02287376
- Testing
- Diclofenac Potassium for Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Pediatric Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
- Trial name
- NCT04649242
- Testing
- Rimegepant/BHV3000
- Where
- 246 sites in United States, Canada and 7 more
- Volunteers
- 2,100 people
- Sponsor
- Pfizer
Migraine
An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine
The purpose of this protocol is to allow subjects who completed any BHV3000 (rimegepant) clinical study to continue to have access to rimegepant while collecting ongoing safety data.
- Trial name
- NCT03934086
- Testing
- rimegepant
- Sponsor
- Pfizer
Migraine Disorders
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute…
- Trial name
- Adelphi DSP (NCT06412965)
- Where
- United States
- Volunteers
- 528 people
- Sponsor
- Pfizer
Migraine Disorders, Migraine
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of…
- Trial name
- NCT00240630
- Testing
- sumatriptan succinate/naproxen sodium
- Where
- 50 sites in United States
- Volunteers
- 646 people
- Sponsor
- GlaxoSmithKline
Episodic Migraine, Migraine With Aura
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
This is a prospective, double-blind, sham-controlled, randomized clinical trial . This study aims to assess the efficacy, safety, tolerability, and the optimal dose of the Mi-Helper transnasal cooling device for acute treatment…
- Conditions
- Episodic Migraine, Migraine With Aura, Migraine Without Aura, Migraine
- Trial name
- NCT06051604
- Testing
- Mi-Helper
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- CoolTech LLC
Migraine
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication…
- Trial name
- NCT05509400
- Testing
- Rimegepant
- Where
- 93 sites in United States, Australia and 13 more
- Volunteers
- 813 people
- Sponsor
- Pfizer
Migraine Disorders
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
The purpose of this study is to evaluate the efficacy and safety of a range of doses of oral sumatriptan for the acute treatment of migraine in children ages 10 to 17.
- Trial name
- NCT00963937
- Testing
- Sumatriptan 25 mg, Sumatriptan 50 mg
- Where
- 16 sites in Japan
- Volunteers
- 178 people
- Sponsor
- GlaxoSmithKline
Migraine
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
- Trial name
- UBR Prodrome (NCT04492020)
- Testing
- Ubrogepant 100 mg
- Where
- 73 sites in United States
- Volunteers
- 518 people
- Sponsor
- AbbVie
Migraine With or Without Aura
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
- Trial name
- SPARTAN (NCT02605174)
- Testing
- Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg
- Where
- 95 sites in United States
- Volunteers
- 3,005 people
- Sponsor
- Eli Lilly and Company
Migraine, Head Pain
A Study Comparing the Effectiveness and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Treatment of Acute Pain From a Migraine Headache
The purpose of this study is to evaluate the effectiveness and safety of tramadol HCl/acetaminophen as a pain medication compared with placebo in the treatment of acute pain from a migraine headache.
- Conditions
- Migraine, Head Pain, Headache
- Trial name
- NCT00297375
- Testing
- tramadol HCl/acetaminophen
- Volunteers
- 375 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Migraine
Acute Treatment of Migraine in Pre-Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN)
Migraine is a prevalent neurological disorder that severely impacts both children and adolescents, causing significant disability.
- Trial name
- NCT06138756
- Testing
- Nerivio
- Where
- 2 sites in United States, Israel
- Volunteers
- 293 people
- Sponsor
- Theranica
Migraine With or Without Aura
Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine
To confirm the efficacy of three dose levels of oral eletriptan relative to placebo in relieving symptoms of acute migraine and to further explore the dose response relationship of eletriptan.
- Trial name
- NCT01978496
- Testing
- Eletriptan 20 mg, Eletriptan 40 mg, Eletriptan 80 mg
- Volunteers
- 1,334 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Migraine
Randomized Trial in Adult Participants With Acute Migraines
The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT04571060
- Testing
- Zavegepant
- Where
- 94 sites in United States
- Volunteers
- 1,978 people
- Sponsor
- Pfizer